Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells

by Anna Parente-Ribes, Sigrid S. Skånland, Simone Bürgler, Audun Os, Dong Wang, Bjarne Bogen, Geir E Tjønnfjord, Kjetil Taskén, and Ludvig A. Munthe

Haematologica 2015 [Epub ahead of print]

Citation: Parente-Ribes A, Skånland SS, Bürgler S, Os A, Wang D, Bogen B, Tjønnfjord GE, Taskén K, and Munthe LA. Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells. Haematologica. 2015; 100:xxx
doi:10.3324/haematol.2015.135590

Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells

Anna Parente-Ribes1*, Sigrid S. Skånland2,3*, Simone Bürgler1,4*, Audun Os1, Dong Wang1, Bjarne Bogen1,5, Geir E. Tjønnfjord4, Kjetil Taskén2,3,6# and Ludvig A. Munthe1#

1Centre for Immune Regulation, Institute of Clinical Medicine, University of Oslo, Norway
2Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway
3Biotechnology Centre, K. G. Jebsen Centre for Inflammation Research and K. G. Jebsen Centre for Cancer Immunotherapy, University of Oslo, Oslo, Norway
4Department for Haematology, Oslo University Hospital, Rikshospitalet, Oslo & Institute of Clinical Medicine, University of Oslo, Norway
5KG Jebsen Centre for Influenza Vaccine Research, Institute of Clinical Medicine, University of Oslo, Norway
6Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway

* APR, SS and SB contributed equally to this work

# KT and LAM contributed equally to this work

Corresponding authors: Kjetil Taskén (kjetil.tasken@ncmm.uio.no) & Ludvig A. Munthe (ludvig@medisin.uio.no), phone: +47 9346 1540.

Running title: CD40L activates the BCR pathway in CLL
BCR signaling pathway inhibitors such as Syk inhibitors\(^1\) have shown promise in CLL, a mature B cell cancer where the BCR pathway is constitutively active\(^4\). However, sustained BCR signaling can lead to anergy and apoptosis in a process including IgM downregulation, reduced responsiveness to BCR ligands, high intracellular Ca\(^{2+}\) and activation of BCR pathway kinases\(^4\),\(^5\). Several studies suggest that CLL cells are rescued by combined BCR and CD40L triggering; an anti-apoptosis, activation and differentiation signal is mediated by T helper (Th) cells via CD40L (CD40Ligand, CD154) that binds CD40 on the B cell surface\(^6\)\(^-\)\(^10\). Thus, CLL patients have CLL-specific Th cells that can support CLL cell proliferation in xenografts\(^8\),\(^9\), activated CD40L\(^+\) Th cells co-localize with proliferating CLL cells in pseudofollicles\(^6\),\(^7\), and CLL cells secrete Th attracting chemokines recruiting T cell help\(^6\),\(^9\). It has been unclear how BCR pathway inhibitors impact the microenvironmental help of CLL cells. Here we show that CD40L activated the BCR pathway in CLL cells, including Syk and downstream components. CLL cells were very sensitive to the Syk inhibitors that abrogated CD40L induced blastogenesis and proliferation. This suggests that CLL cells require CD40L-dependent activation of the BCR pathway to overcome negative feedback. Hence CD40 may function as a gatekeeper for the constitutive BCR signals. Treatment with Syk inhibitors may interfere with CLL cell proliferation by blocking CD40L-dependent Syk activation. We also found that normal B cells were not affected by the inhibition, suggesting that treatment could spare the normal B cell compartment.

We stimulated CLL cells (Table S1) or normal B cells with CD40L using human CD40L\(^+\) murine L cell fibroblasts\(^11\) for 6 days and measured proliferation by using the BrdU flow kit (anti-BrdU, 3D4 BD). B cell activation was monitored by CD38 expression on gated CD19\(^+\) cells (HB7; HIB19, eBioscience). CD40L\(^+\) L cells stimulated CLL cell blastogenesis, CD38 expression, generation of CLL...
cell clusters and proliferation of cells in all patients analyzed (Figure 1A-C, Supplementary Figure S1). Blastogenesis and cell clustering was dramatically reduced in the presence of the Syk inhibitor fostamatinib (R406), Figure 1B. Nevertheless, CLL cells were viable and activated as indicated by the expression of the activation marker CD38 (Figure 1C, Supplementary Figure S1). In contrast, both the blastogenesis (9 of 10 patients) and proliferation responses (10 of 10 patients) were inhibited in CLL cells (Figure 1D). We extended the analysis to P505-15, a novel and highly selective Syk-inhibitor. P505-15 inhibited blastogenesis and CLL proliferation (Figure 1D, bottom panel). Remarkably, normal B cells (purified from healthy donors by negative selection kit, Miltenyi) were not inhibited in these assays (Figure 1E).

We proceeded to investigate pathway activation with phosphoflow analyses; samples were prepared using phosphoflow reagents from BD Biosciences (San Jose, CA, USA). Permeabilized cells were barcoded with combinations of esters conjugated to Pacific Blue, Alexa Fluor 488 or Pacific Orange (Molecular Probes/Life Technologies) washed and pooled as described. CD19+ barcoded cells (PE-Cy7, SJ25C1, BD Bioscience) were stained with Alexa Fluor 647-conjuated phospho-specific antibodies and acquired on a FACSCanto II, and analyzed as described.

In agreement with previous reports, we found a higher basal activation of the BCR signaling cascade in CLL cells (Syk (pY525/Y526, Cell Signaling Technologies), PLCγ2 (pY759, BD Biosciences), ERK1/2 (pT202/Y204 Cell Signaling Technologies), data not shown). After ligation with cross-linking anti-BCR, CLL cells increased the levels of activated Syk (pY525/Y526) within 3 minutes (Figure 2A, upper panel), with kinetics similar to that of normal B cells, but with lower signal amplitude. CLL cells also increased Syk (pY525/526) levels after sCD40L stimulation, showing a
delayed response, most evident after 10-30 minutes (Figure 2A, upper panel). This response was higher and significantly different from that seen in normal B cells (Figure 2B). In contrast, sCD40L stimulated NF-κB p65 (pS536) and p38 MAPK (pT180/Y182, both mAbs from Cell Signaling) with similar kinetics in CLL and normal B cells (Figure 2A, lower panels).

The analyses demonstrated that CD40 ligation provided a delayed increase in activated Syk in CLL cells. We next analyzed Syk in CLL cells after 24 h co-culture with CD40L+ L cells or control L cells. The CD40L induced levels of activated Syk (pY525/526) was higher in these long-duration assays (Figure 3A). The CD40L dependent Syk activity was markedly and significantly reduced in the presence of both R406 and P505-15 Syk inhibitors (Figure 3A). We proceeded to test levels of phosphorylation-dependent activation of components of the BCR pathway and found that CD40L stimulation increased the activity of Akt (pS473, Cell Signaling Technologies), BLNK (pY84, BD Biosciences), Btk/Itk (pY551/Y511, BD Biosciences), ERK1/2 (pT202/Y204) in 5 of 5 patients (Figure 3B and data not shown), suggesting that the CD40L pathway activation is permissive for constitutively active signals in the BCR pathway. Syk inhibition to a lesser degree also reduced the activity of the downstream pathway constituents, most pronounced effects were seen with P505-15 and proximal constituents, pAkt, pBtk/Itk (Figure 3B).

In summary, we here report that CD40 ligation resulted in increased activity in the BCR pathway of CLL cells; this included phosphorylation of Syk and the downstream Akt, BLNK, Btk/Itk, and pErk1/2. The CD40L dependent activation was significantly higher in CLL cells than in normal B cells. CD40L stimulation induced CLL cell blastogenesis and proliferation and this response was blocked by Syk inhibition in CLL cells but not in B cells. Taken together, the results suggest that CLL
cells draw advantage of CD40L stimulation by increasing BCR pathway activity, signal integration and CLL cell proliferation. The inhibition of Syk only minimally reduced the CD40L dependent activation of NF-κB1 and CD38 on CLL cells. We find it likely that the difference from normal B cells is linked to constitutive BCR signaling and anergy in CLL cells\(^4\),\(^5\),\(^13\)-\(^15\). Hence, CD40 may act as a gatekeeper for constitutive BCR signals in anergized CLL cells, thereby disinhibiting feedback components. It is suggested, but not yet demonstrated that normal anergic B cells would be similarly dependent upon CD40L and sensitive to Syk-inhibition. If so, Syk-inhibition could play a role in aborting the rescue of anergic autoreactive B cells in autoimmune disease. Although yet to be demonstrated, CD40 dependent Syk activation may be necessary in CLL cells to overcome the negative effects of Lyn/SHP-1\(^13\) or inositol phosphate phosphatases\(^14\),\(^15\) to allow full CLL activation and CLL cell proliferation.

Fostamatinib had an objective response in 55\% of CLL patients treated with the drug in a phase II trial, the highest response rate in this study that also included other B cell malignancies\(^1\). Other Syk-inhibitors including P505-15\(^2\) are now being developed and tested with promising results\(^3\). Recently the novel Syk inhibitor entospletinib had an objective response of 61\% in phase II for relapsed or refractory CLL\(^3\), further trials are under way (NCT01799889, NCT01796470) and also include trials of a combined Syk/JAK inhibitor (NCT01994382). These impressing findings have yet to be followed up in phase III clinical trials. However, the demonstration of marked Syk sensitivity in CLL cells as compared to normal B cells as presented herein clearly suggest that further clinical trials are indicated.
Footnotes:

APR, SB, SS, AO, DW, and LAM performed the experiments. GET performed patient selection, evaluation and gathered samples. APR, SB, SS, AO, DW, GET, BB, KT and LAM evaluated and analyzed the data. APR, SB, SS, KT and LAM designed experiments and wrote the manuscript.

Funding:

This work was supported by grants from the University of Oslo, Oslo University Hospital Rikshospitalet, the South-Eastern Norway Regional Health Authority, The Swiss National Science Foundation, The Norwegian Cancer Society, The Research Council of Norway, CoE funding 179573/V40 and FriMedBio (204784/V40).
Figure Legends

Figure 1. Analysis of Syk inhibition of CD40 signaling in CLL and normal B cells

A-D. CLL cells were stimulated by irradiated CD40L⁺ or untransfected L cells in the presence of R406, P505-15 (SelleckChem) using relevant in vivo concentrations or DMSO vehicle control.

(A) Forward scatter (cell size) vs. BrdU incorporation (anti-BrdU, 3D4 BD Bioscience) analysis (day 5) in the gated CD19⁺ CLL cells as indicated.

(B) Microscopic analysis (day 3) in the absence (top) or presence (bottom) of R406 (5μM). CLL cells were stimulated with irradiated CD40L⁺ L cells.

(C) Expression of the activation marker CD38 on CLL cells (top) or normal negatively selected B cells (Miltenyi selection kit, bottom) as indicated.

(D and E) B cells were stimulated by irradiated CD40L⁺ L cells. Left: Forward scatter vs. BrdU incorporation analysis (day 5) in the gated CD19⁺ CLL cells, (D) and CD19⁺ normal B cells (E) as indicated. The distribution of cells with high FSC (blasts, right quadrants) and proliferation (BrdU⁺, upper quadrants) are shown. Right panel: gated CD19⁺ CLL cells, (D) and CD19⁺ normal B cells (E) stimulated by CD40L in the presence of DMSO or R406 (5 or 50 mM). Blastogenesis (%) was calculated as by subtracting unstimulated background: stimulated CLL cells [upper right (UR) + lower right (LR) quadrants] – unstimulated CLL cells [UR+LR]. Proliferation (%): stimulated CLL cells [upper left (UL) + upper right (UR)] quadrants) - unstimulated CLL cells [UL+UR]. Wilcoxon signed rank test, n=10, P < 0.006 for all comparisons in D; no significant differences in E (n=10). See also Supplementary Table S1 for patient list.

Figure 2. Analysis of Syk activation following CD40 or BCR ligation
(A) CLL cells or normal B cells were stimulated with sCD40L (400 ng/ml, ImmunoTools, Germany) or F(ab’)2 anti-human IgM (10 μg/ml, Southern Biotechnology, USA) for the indicated time periods. CD19+ cells were gated, Syk (pY525/Y526), NF-κB p65 (pS536) and p38 MAPK (pT180/Y182) were identified by phosphoflow cytometry, top and bottom panels, respectively. Shown is arcsinh median difference of the fluorescence intensity signals relative to unstimulated sample at time 0 (dotted line) for each time course in representative samples from one CLL patient and one B cell donor.

(B) Activated Syk (pY525/Y526, as in A) in CLL or B cells 30 minutes after stimulation with sCD40L, n=8 CLL patients, n=8 healthy individuals. Mann Whitney U, p= 0.015.

Figure 3. Analysis of Syk inhibitors on BCR pathway activation in CLL cells stimulated by CD40L

(A) CLL cells from three patients were incubated with CD40L+ or untransfected control L cells for 24h. CLL cells were treated with R406 (10 μM) or P505-15 (2 μM) or vehicle (DMSO). CLL cells were then processed and analyzed as in Figure 2. Syk (pY525/Y526) arcsinh median difference is shown. We found a significant difference between Syk activation in DMSO vs R406 and DMSO vs. P505-15 (paired student t test, p=0.03 and 0.001 respectively). Similar results were obtained with a separate experiment including 2 other patients.

(B) Level of phosphorylation of down-stream signaling proteins in the BCR pathway from experiment as in A. Arcsinh median difference is shown for Akt (pS473), BLNK (pY84), Btk/Itk (pY551/Y511), ERK1/2 (pT202/Y204), and Syk (pY525/Y526). Heat map corresponds to -0.55 – +0.55 as indicated in the color bar.
Supplementary Figure S1

Expression of the activation marker CD38 on CLL cells after CD40L stimulation and Syk inhibition. CLL cells from 10 patients were stimulated by irradiated CD40L⁺ or untransfected L cells (unstimulated) in the presence of R406 using relevant in vivo concentrations or DMSO vehicle control. See also Figure 1C.

(A) Expression of the activation marker CD38 on CD19⁺ CLL cells is shown in unstimulated condition, after CD40L stimulation with vehicle (DMSO) only, or after CD40L stimulation in the presence of R406.

(B) Mean fluorescent intensity of CD38-expression in CD19⁺CLL cells as shown in (A).

<table>
<thead>
<tr>
<th></th>
<th>MFI: Unstim + R406 (50µM)</th>
<th>MFI: CD40L + DMSO</th>
<th>MFI: CD40L + R406 (50µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLL105</td>
<td>18</td>
<td>62</td>
<td>22</td>
</tr>
<tr>
<td>CLL106</td>
<td>3.7</td>
<td>19</td>
<td>15</td>
</tr>
<tr>
<td>CLL109</td>
<td>11</td>
<td>19</td>
<td>19</td>
</tr>
<tr>
<td>CLL110</td>
<td>7.5</td>
<td>16</td>
<td>13</td>
</tr>
<tr>
<td>CLL111</td>
<td>4.4</td>
<td>32</td>
<td>33</td>
</tr>
<tr>
<td>CLL119</td>
<td>6.8</td>
<td>28</td>
<td>12</td>
</tr>
<tr>
<td>CLL125</td>
<td>6.4</td>
<td>17</td>
<td>11</td>
</tr>
<tr>
<td>CLL126</td>
<td>7</td>
<td>12</td>
<td>9.2</td>
</tr>
<tr>
<td>CLL121</td>
<td>63</td>
<td>56</td>
<td>48</td>
</tr>
<tr>
<td>CLL132</td>
<td>79</td>
<td>170</td>
<td>62</td>
</tr>
</tbody>
</table>
### Supplemental Table SI. Patient information.

<table>
<thead>
<tr>
<th>Patient identifier</th>
<th>Gender/age (years)*</th>
<th>Binet stage*</th>
<th>IgVH,% homology to germline1</th>
<th>CD38 (%)2</th>
<th>FISH</th>
<th>Observation time before treatment / Treatment (T)3</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLL105</td>
<td>F/56</td>
<td>A</td>
<td>VH3-23, 100 VH3-49, 94.8 (biallelic)</td>
<td>0</td>
<td>NA</td>
<td>96/Not T</td>
</tr>
<tr>
<td>CLL106</td>
<td>F/52</td>
<td>A</td>
<td>VH3-23, 95.2</td>
<td>1</td>
<td>NA</td>
<td>49/Not T</td>
</tr>
<tr>
<td>CLL107</td>
<td>M/38</td>
<td>A</td>
<td>VH3-30, 92.9</td>
<td>1</td>
<td>del(13q14)</td>
<td>84/Not T</td>
</tr>
<tr>
<td>CLL109</td>
<td>M/54</td>
<td>A</td>
<td>VH3, 93.8</td>
<td>1</td>
<td>NA</td>
<td>61/Not T</td>
</tr>
<tr>
<td>CLL110</td>
<td>M/49</td>
<td>A</td>
<td>VH6-01, 95.4</td>
<td>1</td>
<td>NA</td>
<td>89/Not T</td>
</tr>
<tr>
<td>CLL111</td>
<td>M/59</td>
<td>A</td>
<td>VH1-69, 91</td>
<td>2</td>
<td>NA</td>
<td>48/Not T</td>
</tr>
<tr>
<td>CLL114</td>
<td>M/55</td>
<td>A</td>
<td>VH3-23, 88.2</td>
<td>2</td>
<td>NA</td>
<td>78/Not T</td>
</tr>
<tr>
<td>CLL119</td>
<td>M/56</td>
<td>C</td>
<td>VH3-21, 98.7</td>
<td>NA</td>
<td>Normal karyotype</td>
<td>5/FCA</td>
</tr>
<tr>
<td>CLL121</td>
<td>M/64</td>
<td>C</td>
<td>VH4-39, 98.7</td>
<td>61</td>
<td>Normal karyotype</td>
<td>1/FCA</td>
</tr>
<tr>
<td>CLL125</td>
<td>M/44</td>
<td>A at diagnosis, progressed to C</td>
<td>VH1-18 98,1/ VH3-30 97.3 (biallelic)</td>
<td>0</td>
<td>Normal karyotype</td>
<td>10/FCA</td>
</tr>
<tr>
<td>CLL126</td>
<td>F/55</td>
<td>C</td>
<td>VH4-34, 95.4</td>
<td>1</td>
<td>del(13q14)</td>
<td>F-FC-FCR-A</td>
</tr>
<tr>
<td>CLL132</td>
<td>M/51</td>
<td>B</td>
<td>VH3-30, 100</td>
<td>94</td>
<td>del(13q14)</td>
<td>29/FC</td>
</tr>
<tr>
<td>CLL135</td>
<td>M/61</td>
<td>A at diagnosis, progressed to C</td>
<td>VH4-34, 100</td>
<td>50</td>
<td>Normal karyotype</td>
<td>36/FCR-A-BR</td>
</tr>
<tr>
<td>CLL136</td>
<td>F/66</td>
<td>A</td>
<td>VH3-30, 91.9</td>
<td>1</td>
<td>del(13q14)</td>
<td>52/Not T</td>
</tr>
</tbody>
</table>

* :at diagnosis
NA: Not analyzed.
1 IgVH family, percent homology to germline.
2 Percentage of cells staining positive for CD38, above isotype control.
3 Observation time, treatment-free months since diagnosis. Non-treated patients are marked with Not T. Treated patients have received regimens with the following drugs marked with abbreviations: F= Fludarabine; C = Cyclophosphamide; A=Alemtuzumab; R=Rituximab; BR=bendamustine. Cells were gathered before treatment except for CLL126 and CLL135. Patient CLL126 was initially treated with F, thereafter with FC, then FCR (aborted due to toxicity), and replaced by A monotherapy. Samples for CLL126 were gathered prior to FCR treatment. Patient CLL135 was initially treated with FCR, then A and finally BR. Samples were gathered between 2nd and 3rd treatment.